Hematology, Medical Oncology, Molecular Targeted Therapies
Conditions
Brief summary
The objective of this study is to show the interest of setting up a drug vigilance card in Oncology in order to reinforce patient safety, develop compliance and avoid drug interactions when the patient consults town professionals or other specialists.
Detailed description
Recent developments in oral chemotherapy and targeted therapies have radically changed cancer patient management; ambulatory care is now common. Oral therapies afford many advantages, improving patient quality of life and autonomy by reducing hospital stays and involving patients in their own care. Optimising the care of cancer patients at home requires the coordinated intervention of hospital and town healthcare professionals and involvement of the patient to detect, prevent, and manage adverse events, avoid drug interactions, and educate patients. Preliminary work in haematology has highlighted (n = 31 patients) the interest of a "drug vigilance card" in three indications (Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia and Multiple Myeloma) with an increase in the town-hospital link. This is an prospective cohort study. Following the announcement consultation, in addition to the personalised care plan, the information about the treatment will be contained in a drug monitoring card that will be given to the patient by the health professional (doctor or nurse). This drug monitoring card should be presented to the health professionals by the patient. During the entire period of treatment, the patient will have a card.
Interventions
None listed
Sponsors
University Hospital, Limoges
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* All patients treated at Limoges University Hospital in Medical Oncology department, receiving oral treatment (chemotherapy and/or targeted therapies)
Exclusion criteria
* All patients treated at Limoges University Hospital in Medical Oncology department, receiving hormone therapy or IV treatment only.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| measure patient satisfaction at 3 months | 3 months | Patient satisfaction will be evaluated using IBM computer usability satisfaction questionnaires published by James R. Lewis (https://doi.org/10.1080/10447319509526110) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of caregiver satisfaction | 3 months | Caregiver satisfaction will be evaluated using IBM computer usability satisfaction questionnaires published by James R. Lewis (https://doi.org/10.1080/10447319509526110) |
| Measurement of compliance reported by the GIRERD questionnaire | 3 months | patients will have to answer shorts questions on GIRERD\* questionnaire to evaluate their Medication compliance to oral anticancer drugs. \*X. Girerd, O. Hanon, K. Anagnostopoulos, C. Ciupek, J.J. Mourad, S. Consoli Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic Presse Med, 30 (2001), pp. 1044-1048 |
| Measuring the satisfaction of treating physicians and health professionals | 3 months | Treating physicians ad health professionnals satisfaction will be evaluated using IBM computer usability satisfaction questionnaires published by James R. Lewis (https://doi.org/10.1080/10447319509526110) |
| Evaluate the use of the QR code by health professionals/carers | 3 months | The use of the QR code with be evaluated by counting how many times it will be flashed during study period. |
Countries
France
Outcome results
None listed